Bettina heeft ruime ervaring in het adviseren van kleine en middelgrote biotech bedrijven, in het bijzonder op het gebied van kankertherapieën, en in het opstellen van octrooieerbaarheids-, geldigheids- and FTO-analyses voor investeerders. Zij vertegenwoordigt cliënten in oppositieprocedures voor het Duitse octrooi- en merkenbureau en het Europees Octrooibureau en in nietigheidsprocedures voor de federale octrooirechtbank en in inbreukprocedures voor de Duitse regionale rechtbanken.

Bettina is hoofd van de vestiging van V.O. in München. Zij is redactielid van de nieuwsbrief van V.O. en voormalig bestuurslid van Women in IP e.v.

In haar hoedanigheid van European Patent Litigator, is Bettina bevoegd om als UPC representative op te treden.

Werkervaring

• Octrooi- en merkengemachtigde, V.O. (2008-heden)
• European Litigator, CEIPI (2010-heden)
• Postdoc, IGBMC in Illkirch Strasbourg, France (1999-2001)
• Postdoc, the Max-Planck-Institute of Psychiatry (1999)

Opleiding

• PhD, Max-Planck-Institute of Psychiatry i.s.m. Technical University Munich (1998)
• Diploma (vergelijkbaar met master´s degree), Biologie (1995)

Directories

• “Bettina Hermann is valued for her advice on patent prosecution and opinion work for biotechnology and pharmaceutical clients. She delivers responsive and accurate advice, providing clear and practical strategic guidance. Her approach is professional, reliable and client-focused, supporting confident decision-making on European patent matters” (IAM Patent 1000, 2026)
• “Bettina Hermann is “a highly sophisticated patent attorney operating in the biotechnology and pharmaceutical space. She draws on her in-depth knowledge to develop strong strategic plans for her clients’ patent portfolios. Notably, she manages the portfolio of Secarna, a leading independent European antisense drug discovery company” (IAM Patent 1000, 2024, 2025)
• “For chemical and biological inventions, companies look to the 20-plus years of experience of attorney Bettina Hermann. Hermann has particular technical proficiency in cancer therapies. She is also routinely turned to for commercial patent advice – including FTO analyses” (IAM Patent 1000, 2023)
• “For dynamic emerging and established biotechnology companies, Bettina Hermann is just the ticket with her highly cultivated drafting skills and strategic wisdom. She stays the course in lengthy examination proceedings and emerges with ironclad protections for her clients’ cornerstone innovations” (IAM Patent 1000, 2021).
• Recognized as IP Star (2018 – 2026) by Managing Intellectual Property.
• Recommended Individual (IAM Patent 1000, 2020 – 2026).
• “Bettina Hermann, who works out of V.O., ‘provides excellent and timely advice, always with a kind and helpful manner’ in her preferred fields of microbiology, genetics and chemistry” (IAM Patent 1000, 2019).
• “Biotechnology authority Bettina Hermann at V.O. is assiduous in her drafting of applications; nothing escapes her gimlet eye” (IAM Patent 1000, 2018).

Nevenactiviteit

• Lid van Association of Intellectual Property Experts
• Lid van AIPPI (Association International pour la Protection de la Propriété Intellectuelle)
• Lid van FICPI (Fédération Internationale de la Conseils en Propriété Industrielle)
• Lid van LES (Licensing Executives Society)
• Lid van GRUR (German Association for Intellectual Property and Copyright e.V.)
• Lid van EPI (European Patent Institute)
• Lid van German Patent Bar Association

Publicaties

• B.C. Hermann, “Interaction of neurosteroids and neurosteroid receptors of the serotonergic and dopaminergic system”, 1998, PhD at the Max-Planck-Institute of Psychiatry, Munich, in the department of Prof. Dr. Dr. Holsboer in cooperation with the Technical University Munich, department of biochemistry.

Talen

• Engels
• Duits
• Frans